BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 6641090)

  • 1. Cardioselectivity of prenalterol and isoproterenol.
    Jennings G; Bobik A; Oddie C; Hargreaves M; Korner P
    Clin Pharmacol Ther; 1983 Dec; 34(6):749-57. PubMed ID: 6641090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol.
    Jennings G; Bobik A; Oddie C; Restall R
    Clin Pharmacol Ther; 1984 May; 35(5):594-603. PubMed ID: 6143634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echocardiographic comparison between prenalterol and dobutamine.
    Wester HA; Oltmanns D
    Acta Med Scand Suppl; 1982; 659():181-90. PubMed ID: 6127888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive assessment of chronotropic and inotropic response to preferential beta-1 and beta-2 adrenoceptor stimulation.
    Corea L; Bentivoglio M; Verdecchia P; Motolese M; Sorbini CA; Grassi V; Tantucci C
    Clin Pharmacol Ther; 1984 Jun; 35(6):776-81. PubMed ID: 6145533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the hemodynamic effects of prenalterol and isoprenaline in patients with complete heart block.
    Svendsen TL; Pelle H; Lønholt C; Bonde J; Kampmann JP; Lindeneg O
    J Cardiovasc Pharmacol; 1984; 6(4):693-6. PubMed ID: 6206327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotropic, chronotropic and dromotropic effects of prenalterol, a new cardiostimulant drug.
    Moore EN; Aberg G; Spear JF; Hodess AB; Herrmann I; Adler G
    Acta Med Scand Suppl; 1982; 659():53-70. PubMed ID: 6958179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.
    Rönn O; Fellenius E; Graffner C; Johnsson G; Lundborg P; Svensson L
    Eur J Clin Pharmacol; 1980 Feb; 17(2):81-6. PubMed ID: 6102914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of selective and nonselective beta-agonists on plasma potassium and norepinephrine.
    Vincent HH; Boomsma F; Man in't Veld AJ; Derkx FH; Wenting GJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1984; 6(1):107-14. PubMed ID: 6199591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Echocardiographic measurements of hemodynamic effects and pharmacokinetics of prenalterol (author's transl)].
    Oltmanns D; Wester HA; Stein R
    Z Kardiol; 1981 May; 70(5):394-8. PubMed ID: 6115520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hemodynamic actions of prenalterol in left ventricular failure.
    Awan NA; Evenson MK; Needham KE; Mason DT
    Acta Med Scand Suppl; 1982; 659():251-61. PubMed ID: 6127893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic effects of prenalterol in healthy subjects.
    Johnsson G
    Acta Med Scand Suppl; 1982; 659():109-22. PubMed ID: 6127882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventilatory and haemodynamic effects of prenalterol and terbutaline in asthmatic patients.
    Greefhorst AP; van Herwaarden CL
    Eur J Clin Pharmacol; 1983; 24(2):173-8. PubMed ID: 6132819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The haemodynamic effects of intravenous prenalterol and ouabain in conscious dogs.
    Ek L; Björkman JA; Carlsson E; Johansson B
    Acta Med Scand Suppl; 1982; 659():39-52. PubMed ID: 6127899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.
    Rasmussen S; Høilund-Carlsen PF; Hesse B; Hartling OJ; Fabricius J; Dige-Petersen H; Giese J
    Eur J Clin Pharmacol; 1984; 27(5):539-43. PubMed ID: 6151507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: measurement of agonist affinity by alteration of receptor number.
    Kenakin TP; Beek D
    J Pharmacol Exp Ther; 1984 May; 229(2):340-5. PubMed ID: 6143816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenalterol: a partial beta 1-adrenoceptor agonist or a beta-blocker with intrinsic activity?
    Wirtzfeld A; Klein G; Bibra HV; Sauer E
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):20-7. PubMed ID: 2859252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamics and leg muscle metabolism at rest and during exercise in young healthy men after prenalterol.
    Dahlström U; Atterhög JH; Jorfeldt L
    Clin Pharmacol Ther; 1983 Jun; 33(6):701-9. PubMed ID: 6851402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta 1-and beta 2-adrenoceptor stimulatory effects of prenalterol.
    Mattsson H; Andersson T; Carlsson E; Hedberg A; Lundgren B; Olsson T
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Dec; 321(4):302-8. PubMed ID: 6132344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose response study with oral prenalterol in patients with chronic congestive cardiac failure.
    Hendry WG; Comerford MB; Besterman EM
    Clin Cardiol; 1984 Jan; 7(1):23-8. PubMed ID: 6705284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.